TYRATyra Biosciences, Inc.

HealthcareUSD
$26.23

The financials

Tyra Biosciences, Inc. by the numbers

Tyra Biosciences, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$49M−$31Mn/a
Net income−$46M−$28Mn/a
Diluted EPS−$0.69−$0.47n/a

Biotechnology

Ranks #101 of 145 by Smart Score

Compare peers
GLUE+3.9%
Monte Rosa Therapeutics, Inc.
RAPP-2.7%
Rapport Therapeutics, Inc.
MESO-6.8%
Mesoblast Limited
IOVA-0.94%
Iovance Biotherapeutics, Inc.
STOK+0.03%
Stoke Therapeutics, Inc.
LKFT-0.59%
Lakefront Biotherapeutics NV